Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

18.79
-0.4300-2.24%
Post-market: 19.150.3600+1.92%19:34 EDT
Volume:1.67M
Turnover:31.88M
Market Cap:1.98B
PE:-14.28
High:19.73
Open:19.39
Low:18.66
Close:19.22
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.66
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.30
PE(LYR):-2.64

Loading ...

U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop

Reuters
·
Mar 26

Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 26

Sarepta Therapeutics Inc : Piper Sandler Raises Target Price to $23 From $16

THOMSON REUTERS
·
Mar 26

ETF Daily | SRPU Soars 69%; FLYT Surges 37%; ARMG Jumps 33%; Space and Semiconductor Themes Lead

ETF Tracker
·
Mar 26

Urban-gro, DraftKings, Sarepta Therapeutics, Destiny Tech100 And AMD: Why These 5 Stocks Are On Investors' Radars Today

Benzinga_recent_news
·
Mar 26

U.S. Small Caps Rise; Sarepta Therapeutics Climbs Highest

Dow Jones
·
Mar 26

Sarepta price target raised to $25 from $20 at Morgan Stanley

TIPRANKS
·
Mar 26

BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings

Reuters
·
Mar 26

Sarepta Therapeutics Up Over 30%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk

Dow Jones
·
Mar 26

These Stocks Are Today's Movers: Arm, Intel, Firefly Aerospace, Robinhood, Sarepta, JD.com, and More -- Barrons.com

Dow Jones
·
Mar 26

Shares of This Gene Therapy Maker Are Up 29%. The Safety Debate Is Far From Over. -- Barrons.com

Dow Jones
·
Mar 26

Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink

TIPRANKS
·
Mar 25

Sarepta early DM1 data ‘appear promising,’ says Oppenheimer

TIPRANKS
·
Mar 25

Sarepta Therapeutics' Early Trial Results of siRNA Treatments Show High Muscle Concentrations in Neuromuscular Diseases

MT Newswires Live
·
Mar 25

Shares of Sarepta Therapeutics up 3.2% Premarket After Muscle Disease Drugs Show Promise in Early-to-Mid Stage Trials

THOMSON REUTERS
·
Mar 25

BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1

Reuters
·
Mar 25

BUZZ-Sarepta rises after muscle disease drugs show promise in early-to-mid stage trials

Reuters
·
Mar 25

Sarepta Therapeutics Inc - Proof-of-Concept Data Show Single Dose of Srp-1001 and Srp-1003 Reduces Target Protein or Mrna

THOMSON REUTERS
·
Mar 25

Sarepta Therapeutics Inc - Majority of Adverse Events in Studies Were Mild to Moderate and Not Dose Dependent

THOMSON REUTERS
·
Mar 25

Sarepta Therapeutics Inc - Sirna Achieves High Muscle Concentrations Without Dose Limiting Toxicity for Fshd1 and Dm1

THOMSON REUTERS
·
Mar 25